English
ATHENA owl emblemATHENAGlauxIntelligence

Every outlet that reported this event flows into it - two or more independent sources make it verified.

Businessemerging

Sofinnova closes second crossover fund at €725M for late-stage European biotechs

Sofinnova Partners has secured €725 million ($815 million) for its second crossover fund, which it said would fill the financing gap for late-stage European biopharma and medtech companies. from Endpoints News

In brief

Reported independently by 3 outlets in 2 countries since 16 Nov, first by BioPharma Dive; coverage is just emerging. ATHENA finds no risk indicators in the coverage. Confidence is 60% (moderate), with 3 independent outlets corroborating it and an average source reliability of 68%. Outlets by country: United States (2), United Kingdom (1). Coverage: 16 Nov to 16 Nov, 3 hours.

Why it matters: Company and investment news shows where capital is moving and which sectors are gaining or losing ground.

What changed: 3 new reports from 3 outlets in the 24 hours to 16 Nov.

First reported as: One of Europe’s leading VCs banks a €725M ‘crossover’ fund

AutomatedSelected, grouped and scored by ATHENA's published method from 3 independent outlets. The headline is the outlet's own; ATHENA's sentences follow fixed patterns - no generative AI writes them. How it works →

How alerts work

How to read this page

What you are reading
3 outlets in 2 countries reported this event. The reports below are listed in the order they appeared; each headline opens the original article. ATHENA writes none of the reports.
Our reading
For the record — The reports describe a completed, domestic, commercial or personal matter. We list it so you can see who reported it and when. We are not tracking a risk of wider conflict here.
How much evidence
Limited Treat this page as an early report.

After repeats, off-topic items and stale reports are removed, 3 of the 3 listed reports are counted; 100% of the headlines match the event.

What this does not mean
ATHENA measures how an event is reported, not whether it is true. This is not a forecast, a judgement on who is right, or advice.
What would change it
Reports from other independent outlets showing a different development, or a firm confirmation or denial from an official source.

Reading R2 · refreshed with every update of this page. ATHENA has not yet published a track record for these readings; when it does, it will be linked here.

At a glance

3.8Importance
0.0Risk · none detected
60%Confidence

How we score this ›

Selected, scored and written by ATHENA's published methodology. No editor intervenes in individual events. How this is produced ›

Coverage: reports per hour
Coverage: reports per hour
16 Nov 07:00 UTC2
16 Nov 08:00 UTC0
16 Nov 09:00 UTC1

Why these numbers

Importance

Cross-category span
3 subject area(s)
Reach
2 countries
Novelty vs the archive
84 % new
Breadth
3 outlets
Speed
0.5 per hour

Risk

—

Confidence

Independent corroboration
3 independent outlet(s), 3 original report(s) (0 wire copies excluded)
Reliability of the reporting sources
mean 68 % over 3 rated outlet(s)
Stability of the reporting
0 % silently edited · 0 % estimated dates · 0 disputed claim(s)
Independent countries
2 countries
Agreement of the classification
47 %

The reporting — who reported it, and when

headline as published · opens the original
  1. BioPharma Dive · United States
    One of Europe’s leading VCs banks a €725M ‘crossover’ fund
  2. Endpoints News · United States
    Sofinnova closes second crossover fund at €725M for late-stage European biotechs
  3. Pharmaceutical Technology · United Kingdom
    Sofinnova Partners backs European life sciences sector with €725M raise
Help